Finoriq research workspace
Roivant Sciences Ltd. (ROIV) SEC Filings & Filing Highlights
In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform. Review ROIV SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
- Company
- Roivant Sciences Ltd. (ROIV)
- Ticker
- ROIV
- Market Cap
- $24.7B
- Latest Price
- $34.28
- Industry
- Biotech & Pharma
Roivant Sciences Ltd. (ROIV) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Roivant Sciences Ltd. (ROIV).
| Event | Form | Date |
|---|---|---|
| Roivant Sciences Ltd.: Earnings or resultsOn May 20, 2026, Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fourth quarter and f... | 8-K2.02 | 2026-05-20 |
| Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Li...Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Re... | 8-K7.01 | 2026-04-02 |
| Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Li...Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Re... | 8-K2.02 | 2026-04-02 |
| Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement Wi...Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna | 8-K8.01 | 2026-03-03 |
| Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement Wi...Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna | 8-K7.01 | 2026-03-03 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.